Tasurgratinib

他舒替尼

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameTasurgratinib
Drug Alias Nametasurgratinib succinateTASFYGOE-7090
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonists
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 3Fibroblast growth factor receptor 2
Therapy Area/IndicationsSolid tumoursHepatic InsufficiencyBiliary Tract Neoplasms +[6] 
Global Approved IndicationsBiliary Tract Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2024/09/24
Country/TerritoryUnited KingdomMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSciclone Pharmaceuticals (Holdings) LtdEisai Co LtdEisai China Inc +[4] 
Inactive CompaniesEisai Ltd
Active IndicationsSolid tumoursHepatic InsufficiencyBiliary Tract Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG